Related coverage linked through entity extraction aliases.
Jul 08, 2026
Studies highlight ferroptosis and cuproptosis in cancer therapy: a DDR1/VEGFR2 inhibitor reverses gastric cancer chemoresistance, GSH-responsive nanoparticles enhance HCC immunotherapy, and nutrient restriction boosts Sorafenib-induced ferroptosis.
Jun 21, 2026
New clinical data for ANKTIVA immunotherapy in lung cancer, a study on EBV-driven resistance via ADAR1 RNA editing, and research on microbiome metabolites modulating immunotherapy response were presented at major conferences and in recent publications.
Mar 11, 2026
Recent studies demonstrate PD-1 antibody combinations improve survival in natural killer/T-cell lymphoma and show activity in previously treated advanced non-small cell lung cancer, with manageable safety profiles across treatment settings.
